{"id":1702,"date":"2023-06-25T17:32:51","date_gmt":"2023-06-25T17:32:51","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/carboplatin\/"},"modified":"2023-06-25T19:41:35","modified_gmt":"2023-06-25T19:41:35","slug":"carboplatin","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/carboplatin\/","title":{"rendered":"Carboplatin"},"content":{"rendered":"

<\/p>\n

Carboplatin<\/h1>\n

CLINICAL USE<\/h3>\n

Antineoplastic agent:<\/p>\n

  • Ovarian carcinoma of epithelial origin<\/li>\n
  • Small cell carcinoma of the lung
    \n

    DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

    Dose = Target AUC \u00d7 [GFR (mL\/min) + 25]where AUC is commonly 5 or 6 depending on protocol used (Calvert equation)<\/p>\n

    PHARMACOKINETICS<\/h3>\n<\/li>\n
  • Molecular weight                           :371.2<\/li>\n
  • %Protein binding                           :29\u201389<\/li>\n
  • %Excreted unchanged in urine     : 32\u201370<\/li>\n
  • Volume of distribution (L\/kg)       :0.23\u20130.28<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :1.5\u20136\/ Increased
    \n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : Dose as in normal renal function. See \u2018Other Information\u2019<\/li>\n
  • 10 to 20     : Dose as in normal renal function. See \u2018Other Information\u2019<\/li>\n
  • <10           : Dose as in normal renal function. See \u2018Other Information\u2019
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :Unknown dialysability. Dose as in GFR <10 mL\/min<\/li>\n
  • HD                     :Dialysed. Dose as in GFR<\/li>\n
  • <10           : mL\/min<\/li>\n
  • HDF\/high flux   :Dialysed. Dose as in GFR<\/li>\n
  • <10           : mL\/min<\/li>\n
  • CAV\/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL\/min
    \n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugs<\/li>\n

  • Aminoglycosides: increased risk of nephrotoxicity and possibly ototoxicity with aminoglycosides, capreomycin, polymyxins or vancomycin<\/li>\n
  • Antipsychotics: avoid concomitant use with clozapine, increased risk of agranulocytosis
    \n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    \u2013<\/p>\n

    Route<\/h4>\n

    IV<\/p>\n

    Rate of Administration<\/h4>\n

    IV infusion<\/h4>\n

    over 15\u201360 minutes<\/p>\n

    Comments<\/h4>\n<\/li>\n
  • Therapy should not be repeated until 4 weeks after the previous carboplatin course<\/li>\n
  • May be diluted with glucose 5%, or sodium chloride 0.9% to concentrations as low as 0.5 mg\/mL
    \n

    OTHER INFORMATION<\/h4>\n<\/li>\n
  • Patients with abnormal kidney function or receiving concomitant therapy with nephrotoxic drugs are likely to experience more severe and prolonged myelotoxicity<\/li>\n
  • Blood counts and renal function should be monitored closely<\/li>\n
  • Some units still use a dose in normal renal function of 400 mg\/m2. In this instance, the dose should be reduced to 50% of normal for a GFR of 10 to 20 mL\/min, and to 25% of normal for a GFR <10 mL\/min<\/li>\n
  • There is little, if any, true metabolism of carboplatin. Excretion is primarily by glomerular filtration in the urine, with most of the drug excreted in the first 6 hours. Approximately 32% of the dose is excreted unchanged.<\/li>\n
  • Platinum from carboplatin slowly becomes protein bound, and is subsequently excreted with a terminal half-life of 5 days or more.<\/li>\n","protected":false},"excerpt":{"rendered":"

    Carboplatin CLINICAL USE Antineoplastic agent: Ovarian carcinoma of epithelial origin<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1702","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1702","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1702"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1702\/revisions"}],"predecessor-version":[{"id":2838,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1702\/revisions\/2838"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1702"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1702"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1702"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}